Qube Technologies Secures EPA Approval for Continuous Methane Monitoring
Significance of the EPA Approval
This approval represents a significant development in emissions management for the oil and gas industry. Current regulatory compliance relies on periodic inspections, which capture emissions data at specific points in time. In contrast, Qube's continuous monitoring system provides real-time emissions tracking, allowing operators to detect, quantify, and repair methane leaks more efficiently.
'This EPA approval validates our technology's role in advancing emissions monitoring,' said Alex MacGregor, CEO of Qube Technologies. 'Continuous monitoring equips operators with real-time data, helping them respond quickly to leaks, enhance compliance, and improve environmental performance.'
How Qube's Continuous Monitoring Works
Qube Technologies' platform utilizes calibrated sensors and physics-based data modeling to provide 24/7 methane tracking. Unlike inspection-based methods, which capture emissions data intermittently, Qube's system continuously monitors methane levels and delivers actionable insights in real time.
Under the Periodic Screening method, Qube's system collects methane data over a seven-day period, calculates an average emission rate, and compares it to a regulatory threshold. If emissions remain below the threshold, no additional action is required until the next screening cycle. If emissions exceed the threshold, a follow-up survey is conducted to identify and mitigate leaks. This approach provides operators with flexibility in meeting compliance requirements while maintaining all the benefits of continuous monitoring, including real-time data insights and proactive leak management.
Key Benefits of Qube's EPA-Approved Solution
- Regulatory Compliance – Aligns with EPA New Source Performance Standards (NSPS) OOOOb / Emissions Guidance (EG) OOOOc
- Operational Efficiency – Lowers costs and decreases the need for manual inspections.
- Data-Driven Insights – Provides real-time leak detection and quantification.
- Environmental Impact – Supports proactive methane mitigation and sustainability initiatives.
About Qube Technologies
Qube Technologies is a provider of continuous emissions monitoring solutions, specializing in methane detection and quantification. By combining sensor technology with industry-leading data platforms, Qube enables oil and gas operators to efficiently manage emissions and improve compliance.
Alex MacGregor
Qube Technologies Inc
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Trump Media Delays Registration for Bitcoin ETF
President Donald Trump's media company filed an updated application for its Truth Social Bitcoin ETF last week, delaying its launch date amid caution toward crypto at the Securities and Exchange Commission. The updated filing, which was initially submitted in June, still does not include details such as a fee or ticker symbol. Some say the fund, which will directly track the price of bitcoin, might struggle to differentiate itself. 'Bitcoin is effectively digital gold. [It's] not really being used for transactions the way you know currencies are,' said Jeff DeMaso, founder of the newsletter The Independent Vanguard Advisor. 'How much appetite is there for different flavors of digital gold?' READ ALSO: These ETFs Are Going Nuclear and Are Cyclical ETFs Worth the Boom and Bust? The Bit(coin) Of Your Own Drum Trump's bitcoin ETF is one of three filings from Trump Media, which owns his social media platform Truth Social, the other two being the Truth Social Crypto Blue Chip ETF and the Truth Social Bitcoin and Ethereum ETF. Josh Barone, wealth manager at Savvy Advisors, said that having both a bitcoin fund and a more diversified crypto index fund taps into two distinct markets: the 'ideological retail investor' who wants a Trump-approved product, and the 'broader, crypto-curious crowd.' He added that 'fixed supply dynamics, increasing institutional adoption, and a maturing ETF market' have lowered bitcoin's barriers to entry for investors who wouldn't otherwise get into crypto. Still, DeMaso says the fund is likely to blend into the background compared to other, more established funds. 'I would fully expect the iShares, the Fidelitys of the world to kind of continue to take the bulk of the assets,' he said. 'The ETF space is really winner-takes-all, and that race has already started.' Invest in Gold Thor Metals Group: Best Overall Gold IRA Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase American Hartford Gold: #1 Precious Metals Dealer in the Nation The biggest players in the bitcoin ETF space are: The iShares Bitcoin Trust ETF (IBIT), which has over $88 billion in assets; Fidelity's Wise Origin Bitcoin Fund (FBTC), which has $23 billion in assets; And Grayscale's Bitcoin Trust ETF (GBTC), which has $21 billion in assets. Crypto-Curious. At least in the short run, the product will be successful because of Trump's political base, the fund's media attention and pro-crypto policy tailwinds, Barone said. Long-term viability, however, will depend on the success of its 'initial adoption phase, followed by consistent execution, transparency, and competitive pricing,' he said. 'The branding alone will attract a segment of the market that might otherwise avoid crypto entirely.' This post first appeared on The Daily Upside. To receive exclusive news and analysis of the rapidly evolving ETF landscape, built for advisors and capital allocators, subscribe to our free ETF Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
4 hours ago
- UPI
Entire Swedish church set to be moved to avoid falling into a mine
The Kiruna Church in Sweden is being wheeled away from its original location to avoid damage form an expanding mine. Photo by Fedrik Sandberg/EPA Aug. 19 (UPI) -- An entire Swedish church is set to be relocated to avoid damage from the expansion an iron ore mine underneath it. The 113-year-old Kiruna Church has been uprooted and placed on a trailer and is expected to travel for two days. Residents have started seeing cracks in buildings and roads in nearby areas as the underground iron ore mine, the largest in the world, expanded. Officials have begun moving buildings to a safe distance from the mine. The relocation of the church began with a ceremony, with large crowds watching as the structure rolled forward. "It's a big crowd. People came not just from Kiruna and other parts of Sweden. I heard many different languages being spoken," said culture strategist Sofia Lagerlöf Mättää. "It's like history taking place in front of our eyes." Project Manager Stefan Holmblad Johansson, said: "It's a historic event, a very big and complex operation, and we don't have a margin of error. But everything is under control." Swedish Law states that mining cannot take place under buildings. "There's no risk of people falling through cracks. But fissures would eventually damage the water, electricity, and sewage supply. People have to move before the infrastructure fails," chief executive officer of Kiruna's development company, Robert Ylitalo, explained. One of the most delicate aspects in the church's interior is its great altar painting made by prine Eugen. "It's glued directly onto a masonry wall, so it would have been difficult to remove without damage. So it will remain inside the church during the move, fully covered and stabilized. So will the organ with its 1,000 pipes," said Johansson. The Kiruna Church was voted as Sweden's most beautiful pre-1950 building.
Yahoo
7 hours ago
- Yahoo
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in pre-market on Aug. 19, 2025. FDA Gives Green Signal to Wegovy for MASH On Friday, the company announced that Wegovy had been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. The treatment is to be used in combination with a reduced-calorie diet and increased physical activity. First GLP-1 Therapy Approved for MASH The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the ESSENCE Trial The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy's superior efficacy over placebo in improving liver fibrosis. Notably, 62.9% of participants on Wegovy achieved the resolution of steatohepatitis with no worsening of fibrosis compared to 34.3% on placebo. About 36.8% achieved improvement in liver fibrosis without worsening steatohepatitis after 72 weeks versus 22.4% on placebo. The second phase of the trial is expected to conclude in 2029. Market Impact Novo Nordisk confirmed that Wegovy would be immediately available in the United States for MASH treatment. Currently, the only other FDA-approved therapy for MASH is Madrigal Pharmaceuticals' Rezdiffra, which received clearance in 2024. This means Novo Nordisk's Wegovy should make a killing from businesses generated from MASH treatment. NVO-Heavy ETFs in Focus Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) that are heavy on Novo Nordisk. The NVO has solid exposure to ETFs like Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and VanEck Pharmaceutical ETF PPH. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report VanEck Pharmaceutical ETF (PPH): ETF Research Reports Amplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
